KHRN.V - Khiron Life Sciences Corp.

TSXV - TSXV Delayed Price. Currency in CAD
1.5900
-0.1600 (-9.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close1.7500
Open1.7100
Bid1.5900 x 0
Ask1.5800 x 0
Day's Range1.5300 - 1.7450
52 Week Range0.9100 - 4.3500
Volume1,235,808
Avg. Volume488,981
Market Cap175.604M
Beta (3Y Monthly)4.09
PE Ratio (TTM)N/A
EPS (TTM)-0.4360
Earnings DateMay 30, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est5.58
  • Khiron Provides Progress Update on Fully Operational and GMP Compliant Colombian Lab Facilities
    PR Newswire

    Khiron Provides Progress Update on Fully Operational and GMP Compliant Colombian Lab Facilities

    State-of-the-art, 14,000 square foot GMP compliant cannabis extraction lab and ISO 17025 compliant cannabis testing lab includes full capabilities in Ultra high and High performance liquid chromatography ...

  • Market Exclusive

    Cannabis Stock News Daily Roundup August 21

    Cannabis provider Liberty Health Sciences (CSE: LHS) (OTCQX: LHSIF) announced the sale of certain of its assets in Florida and substantially all of its assets in Ohio. The company is selling 36 acres of land, comprising its Chestnut Hill Tree Farm site in Alachua County, Florida, as well as all of its assets in Ohio, […]The post Cannabis Stock News Daily Roundup August 21 appeared first on Market Exclusive.

  • How Khiron Life Sciences Corp. (CVE:KHRN) Could Add Value To Your Portfolio
    Simply Wall St.

    How Khiron Life Sciences Corp. (CVE:KHRN) Could Add Value To Your Portfolio

    I've been keeping an eye on Khiron Life Sciences Corp. (CVE:KHRN) because I'm attracted to its fundamentals. Looking...

  • CNW Group

    Khiron Announces DTC Eligibility, Increasing Access for U.S. Investors

    TORONTO , Aug. 20, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt:A2JMZC), an integrated cannabis company with core operations in Latin America, announced today that its shares have received Depository Trust Company (DTC) full-service eligibility in the United States . DTC eligibility is expected to simplify the process of trading and transferring of the Company's common shares in the United States .

  • PR Newswire

    Khiron Provides Clarification of August 12, 2019 News Release

    TORONTO, Aug. 14, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, wishes to clarify specific disclosure relating to the news release disseminated by the Company on August 12, 2019. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America. Khiron has core operations in Latin America and is fully licensed in Colombia for the cultivation, production, domestic distribution, and international export of both tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis.

  • PR Newswire

    Khiron Boosts European Expansion With Key Executive Appointments

    Experienced capital markets leader and cannabis industry executive Tejinder Virk is appointed President of Khiron Europe Accomplished cannabis legal expert Franziska Katterbach joins Company as Chief Legal ...

  • CNW Group

    Khiron Launches Revenue-Generating Pilot Program With Top Colombian Health Insurance Provider

    Khiron Launches Revenue-Generating Pilot Program With Top Colombian Health Insurance Provider

  • CNW Group

    Khiron Signs Kuida Distribution Agreement with Grupo Éxito, South America's Market Leading Retail Group

    Grupo Éxito has a multinational retail presence in Colombia , Brazil , Argentina and Uruguay and operates 1,533 stores. Kuida to be introduced as key addition to the retailer's cosmetics products category, with experience centres and consultants in each Éxito WOW store to support sales and brand awareness.

  • Benzinga

    Joint Venture Between Khiron Life Sciences, Dixie Brands Receives TSX Conditional Approval

    The previously announced 50/50 joint venture between Khiron Life Sciences Corp. (TSXV: KHRN) and Dixie Brands Inc. (CSE: DIXI.U) has received its conditional approval from the TSX Venture Exchange. The conditional approval will kickstart two endeavors: In the U.S., the distribution and sales of its Kuida cosmeceutical line will soon begin, while Latin America will be introduced to Dixie's CBD-infused line. The joint venture also plans to create new products aimed at the Latin American market.

  • Khiron and Dixie Receive Conditional TSXV Approval for Roll-Out of Kuida Cosmeceutical Line in U.S. Market and Cannabis-Infused Products in Latin America
    CNW Group

    Khiron and Dixie Receive Conditional TSXV Approval for Roll-Out of Kuida Cosmeceutical Line in U.S. Market and Cannabis-Infused Products in Latin America

    Khiron and Dixie Receive Conditional TSXV Approval for Roll-Out of Kuida Cosmeceutical Line in U.S. Market and Cannabis-Infused Products in Latin America

  • CNW Group

    Khiron Provides Update on Canapalife Group Transaction

    TORONTO , Aug. 1, 2019 /CNW/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt:A2JMZC), an integrated cannabis company with core operations in Latin America, today provided an update on the Company's previously announced non-binding LOI with Canapalife Group. The Company confirms the expiry of the LOI and that the parties have mutually agreed not to proceed with the proposed transaction. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America.

  • PR Newswire

    Khiron Begins Pre-clinical Medical Cannabis Studies with Leading Academic Institutes in Uruguay

    Patient-focused studies advance progress towards global clinical trials on Khiron strains to treat inflammation, oxidative and nervous system disorders Co-sponsored with Uruguay government using Company ...

  • PR Newswire

    Khiron Announces Final Approval of Acquisition of NettaGrowth

    TORONTO, July 30, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (KHRN.V), (KHRNF), (Frankfurt: A2JMZC), a medical cannabis company with core operations in Latin America, reports that the Company has received final approval from the TSX Venture Exchange ("TSXV") to close its previously announced acquisition (the "Acquisition") of NettaGrowth International Inc. ("NettaGrowth"), which owns all of the outstanding shares of a Uruguayan company, Dormul S.A. ("Dormul"). As consideration for the Acquisition, Khiron issued 8,498,821 common shares to the shareholders of NettaGrowth, at a deemed price of $1.61 per common share.

  • PR Newswire

    Khiron Life Sciences Added to NYSE-Listed The Cannabis ETF

    TORONTO, July 25, 2019 /PRNewswire/ - Khiron Life Sciences Corp. ("Khiron" or the "Company") (TSXV: KHRN), (KHRNF), (Frankfurt: A2JMZC), an integrated cannabis company with core operations in Latin America, announced today that it has been added to The Cannabis ETF (NYSE:THCX) ("THCX"), which trades on the New York Stock Exchange. Khiron Life Sciences Corp. is positioned to be the dominant integrated cannabis company in Latin America.